TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA approved AbbVie’s once-daily Parkinson’s pill Juvmo (tavapadon) on September 25, as a standalone treatment for early Parkinson’s and an add-on for later stages. Three Phase 3 trials with over 1,300 participants showed improved motor symptoms and extended ‘on time,’ with mild to moderate side effects. AbbVie expects availability in October 2026.
The U.S. Food and Drug Administration has approved AbbVie’s once-daily Parkinson’s pill Juvmo, known as tavapadon during clinical trials, as a standalone treatment for early-stage Parkinson’s disease and as an add-on therapy in later stages. The decision, announced on September 25, gives more than one million Americans living with Parkinson’s a new option designed to control motor symptoms with fewer of the side effects that lead many patients to stop their medications within the first year.
Juvmo is approved for two uses: as a standalone therapy in early Parkinson’s, and as an add-on to existing medications in later stages, where it can prolong the effects of current treatments. AbbVie said it expects the drug to be available in the United States in October 2026.
The approval is based on three 26-week Phase 3 placebo-controlled randomized trials involving more than 1,300 participants. According to the trial results, the first two trials tested Juvmo as a standalone medication and found it produced noticeable and meaningful improvements in motor symptoms — tremors, rigidity, slow movement, and posture problems — with mild to moderate side effects such as nausea and headache. The third trial tested it as an add-on and found it helped prolong “on time,” the period when a Parkinson’s medication is working, and reduce “off time,” when the effects wear off.
Juvmo works differently from existing drugs. In Parkinson’s, dopamine-producing neurons die off, causing motor symptoms. Current medications called dopamine agonists mimic dopamine by activating D2 and D3 receptors — a pathway linked to side effects including dyskinesia (uncontrolled erratic movements) and impulse control disorder, which can cause problematic behaviors such as gambling. Juvmo instead targets the D1 and D5 receptors, activating other dopamine pathways.
Why a D1-Targeting Pill Matters
Many existing Parkinson’s medications must be taken multiple times a day, a burden that compounds as the disease progresses and dosing windows tighten. Because the drugs’ side effects — dyskinesia and impulse control disorder — can be severe, some patients discontinue their medications within the first year, according to Being Patient’s reporting.
By targeting the D1 and D5 receptors rather than the D2 and D3 receptors implicated in many side effects, Juvmo offers physicians a different mechanism in a once-daily format. Dr. Hubert Fernandez, a professor and neurologist at the Cleveland Clinic who served as global investigator on two of the drug’s Phase 3 trials, said in a press release that Parkinson’s treatment has long required balancing dependable motor symptom control against tolerability, and that Juvmo “provides health care providers with greater flexibility to tailor treatment to individual patient needs.”
Dr. Bryan Ho, neurologist and director of the Movement Disorders Program at Tufts Medical Center, offered a measured assessment: “It’s not a huge game-changer, but definitely a nice additional tool to have.” He said he sees it as especially useful for older patients, who are more vulnerable to the side effects of other therapies.
Parkinson’s Treatment Before Juvmo
: “Parkinson’s disease affects over one million people in the U.S. The condition involves the progressive death of neurons that produce dopamine, a neurotransmitter central to movement, which produces the disease’s characteristic motor symptoms: tremors, rigidity, slowed movements, and posture problems.
Existing symptom-treating medications help manage these symptoms but do not stop the underlying disease. Dopamine agonists, which activate D2 and D3 receptor proteins, have been a mainstay, but their side-effect profile — including dyskinesia and impulse control disorder — has limited long-term use. Tavapadon was developed and tested through three Phase 3 trials before receiving FDA approval under the brand name Juvmo.
“It’s not a huge game-changer, but definitely a nice additional tool to have.”
— Dr. Bryan Ho, neurologist and director of the Movement Disorders Program at Tufts Medical Center
Questions the Trials Couldn’t Answer
The three Phase 3 trials each ran for 26 weeks, a duration that, according to Being Patient’s report, is not long enough to determine whether the treatment reduces the risk of impulse control problems compared with existing drugs. Whether the drug’s side-effect advantages hold up over years of use remains untested in the published trial data.
It is also not yet clear how the drug will be priced, whether insurers will cover it without restrictions, or how quickly it will reach pharmacies across the country once it launches in October 2026.
Juvmo’s October Launch and Beyond
AbbVie expects Juvmo to be available in U.S. pharmacies in October 2026. In the months following launch, neurologists will begin prescribing it for early-stage patients as a standalone option and for later-stage patients as an add-on, and real-world data on tolerability and discontinuation rates will start to accumulate.
Longer-term studies or post-marketing surveillance may be needed to answer the question the 26-week trials left open: whether Juvmo’s different mechanism genuinely lowers the risk of impulse control disorder over extended use.
Key Questions
When will Juvmo be available in the U.S.?
AbbVie expects Juvmo to be available in October 2026, roughly a month after the FDA’s September 25 approval.
How does Juvmo differ from existing Parkinson’s medications?
Unlike dopamine agonists, which activate D2 and D3 receptors and are linked to side effects like dyskinesia and impulse control disorder, Juvmo activates the D1 and D5 receptors. It is also taken once daily, unlike many existing drugs that require multiple daily doses.
Can Juvmo be taken alongside other Parkinson’s treatments?
Yes. The FDA approved Juvmo as a standalone treatment for early-stage Parkinson’s and as an add-on treatment in later stages, where trial data showed it prolonged “on time” and reduced “off time.”
What side effects did Juvmo show in trials?
In the Phase 3 trials, participants reported mild to moderate side effects such as nausea and headache. The trials were not long enough to determine whether the drug reduces the risk of impulse control problems compared with existing therapies.
Does Juvmo cure Parkinson’s disease?
No. Like other Parkinson’s medications, Juvmo treats symptoms — motor problems such as tremors, rigidity, and slow movements — but does not stop or reverse the underlying disease. Patients should discuss treatment options with their neurologist.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
